Home › NDC Lookup › RxCUI directory › RxCUI 242831

Griseofulvin 125 MG Oral Tablet — RxCUI 242831

RxNorm drug concept · Semantic clinical drug
RxCUI 242831 Semantic clinical drug · SCD ● Current RxNorm concept 10 FDA products 16 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI242831
Official nameGriseofulvin 125 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped10
Package NDCs mapped16
Reported Medicaid activity (SDUD)6,464 prescriptions · 25 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Griseofulvin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It really can be — and that's one of the most important things to understand about this medication. Fungal infections of the nails especially can take at least 4 to 6 months to cle...
  • How long do I have to take griseofulvin? It seems like a really long time.
  • Yes, and specifically with a fatty meal if you can. Studies show that eating something high in fat — like a full meal with dairy or meat — dramatically increases how much of the me...
  • It's best to avoid alcohol entirely during treatment. The combination of griseofulvin and alcohol has been reported to cause an unpleasant and potentially dangerous reaction — naus...
📖 Read our full Griseofulvin guide →

🕸️ Concept Web — How Griseofulvin 125 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Griseofulvin 125 MG Oral Tablet RxCUI 242831

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Griseofulvin 5021
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Griseofulvin Oral Tablet 372355
    • Griseofulvin Oral Product 1158540
    • Griseofulvin Pill 1158541
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Griseofulvin 125 MG 328323

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Griseofulvin 125 MG SCDC · 328323
  • Griseofulvin Oral Tablet SCDF · 372355
  • Griseofulvin Oral Product SCDG · 1158540
  • Griseofulvin Pill SCDG · 1158541

📦 FDA Products & Package NDCs

10 products · 16 package NDCs
16 package NDCs map to RxCUI 242831 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00115-1724-01 100 TABLET, COATED in 1 BOTTLE, PLASTIC (0115-1724-01) Ultramicrosize Griseofulvin Amneal Pharmaceuticals of New York LLC 2014-09-29
00115-1724-02 500 TABLET, COATED in 1 BOTTLE, PLASTIC (0115-1724-02) Ultramicrosize Griseofulvin Amneal Pharmaceuticals of New York LLC 2014-09-29
00115-1725-01 100 TABLET, COATED in 1 BOTTLE, PLASTIC (0115-1725-01) Ultramicrosize Griseofulvin Amneal Pharmaceuticals of New York LLC 2014-09-29
00115-1725-03 1000 TABLET, COATED in 1 BOTTLE, PLASTIC (0115-1725-03) Ultramicrosize Griseofulvin Amneal Pharmaceuticals of New York LLC 2014-09-29
00781-5827-01 100 TABLET, COATED in 1 BOTTLE (0781-5827-01) Ultramicrosize Griseofulvin Sandoz Inc 2020-04-01
00781-5827-05 500 TABLET, COATED in 1 BOTTLE (0781-5827-05) Ultramicrosize Griseofulvin Sandoz Inc 2020-04-01
00781-5828-01 100 TABLET, COATED in 1 BOTTLE (0781-5828-01) Ultramicrosize Griseofulvin Sandoz Inc 2020-04-01
00781-5828-05 500 TABLET, COATED in 1 BOTTLE (0781-5828-05) Ultramicrosize Griseofulvin Sandoz Inc 2020-04-01
23155-0863-01 100 TABLET in 1 BOTTLE, PLASTIC (23155-863-01) Ultramicrosize Griseofulvin Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc 2023-06-30
23155-0864-01 100 TABLET in 1 BOTTLE, PLASTIC (23155-864-01) Ultramicrosize Griseofulvin Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc 2023-06-30
42794-0013-08 30 TABLET in 1 BOTTLE (42794-013-08) Ultramicrosize Griseofulvin Sigmapharm Laboratories, LLC 2016-05-11
42794-0014-08 30 TABLET in 1 BOTTLE (42794-014-08) Ultramicrosize Griseofulvin Sigmapharm Laboratories, LLC 2016-05-11
62135-0494-01 100 TABLET in 1 BOTTLE, PLASTIC (62135-494-01) Ultramicrosize Griseofulvin Chartwell RX, LLC. 2020-11-30
62135-0494-30 30 TABLET in 1 BOTTLE, PLASTIC (62135-494-30) Ultramicrosize Griseofulvin Chartwell RX, LLC. 2020-11-30
62135-0495-01 100 TABLET in 1 BOTTLE, PLASTIC (62135-495-01) Ultramicrosize Griseofulvin Chartwell RX, LLC. 2020-11-30
62135-0495-30 30 TABLET in 1 BOTTLE, PLASTIC (62135-495-30) Ultramicrosize Griseofulvin Chartwell RX, LLC. 2020-11-30
Observed labelers: Amneal Pharmaceuticals of New York LLC (4) · Chartwell RX, LLC. (4) · Sandoz Inc (4) · Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc (2) · Sigmapharm Laboratories, LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.